Janney Montgomery Scott LLC Increases Stock Holdings in Lantheus Holdings, Inc. (NASDAQ:LNTH)

Janney Montgomery Scott LLC lifted its stake in shares of Lantheus Holdings, Inc. (NASDAQ:LNTH - Free Report) by 34.9% in the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 26,711 shares of the medical equipment provider's stock after buying an additional 6,905 shares during the period. Janney Montgomery Scott LLC's holdings in Lantheus were worth $2,607,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also made changes to their positions in the company. Janus Henderson Group PLC raised its stake in Lantheus by 72.7% in the 4th quarter. Janus Henderson Group PLC now owns 6,198,689 shares of the medical equipment provider's stock worth $554,583,000 after acquiring an additional 2,610,118 shares during the last quarter. Farallon Capital Management LLC increased its holdings in shares of Lantheus by 79.9% in the fourth quarter. Farallon Capital Management LLC now owns 5,316,227 shares of the medical equipment provider's stock valued at $475,590,000 after purchasing an additional 2,361,000 shares during the period. T. Rowe Price Investment Management Inc. raised its stake in shares of Lantheus by 40.5% in the fourth quarter. T. Rowe Price Investment Management Inc. now owns 1,509,332 shares of the medical equipment provider's stock worth $135,025,000 after purchasing an additional 435,445 shares during the last quarter. Raymond James Financial Inc. purchased a new position in shares of Lantheus in the fourth quarter worth about $36,183,000. Finally, Assenagon Asset Management S.A. lifted its holdings in shares of Lantheus by 1,196.4% during the first quarter. Assenagon Asset Management S.A. now owns 336,237 shares of the medical equipment provider's stock worth $32,817,000 after purchasing an additional 310,301 shares during the period. 99.06% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Several equities analysts recently weighed in on the stock. Wall Street Zen upgraded shares of Lantheus from a "hold" rating to a "buy" rating in a report on Thursday, May 8th. Truist Financial cut their price objective on shares of Lantheus from $127.00 to $117.00 and set a "buy" rating on the stock in a research note on Thursday, May 8th. Finally, B. Riley reduced their target price on shares of Lantheus from $122.00 to $109.00 and set a "buy" rating for the company in a report on Monday. Seven analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the stock currently has a consensus rating of "Buy" and an average target price of $130.50.

Lantheus Stock Performance

NASDAQ:LNTH traded up $0.83 during trading hours on Friday, reaching $81.57. The company had a trading volume of 148,963 shares, compared to its average volume of 1,011,294. The company has a debt-to-equity ratio of 0.49, a current ratio of 5.74 and a quick ratio of 5.46. Lantheus Holdings, Inc. has a 1-year low of $73.11 and a 1-year high of $126.89. The business's 50 day moving average price is $85.11 and its 200-day moving average price is $90.75. The firm has a market cap of $5.64 billion, a PE ratio of 23.06 and a beta of 0.11.

Lantheus (NASDAQ:LNTH - Get Free Report) last posted its earnings results on Wednesday, May 7th. The medical equipment provider reported $1.53 earnings per share for the quarter, missing the consensus estimate of $1.64 by ($0.11). Lantheus had a net margin of 16.55% and a return on equity of 36.99%. The firm had revenue of $372.76 million for the quarter, compared to analysts' expectations of $377.37 million. During the same period last year, the firm earned $1.69 earnings per share. Lantheus's revenue for the quarter was up .8% compared to the same quarter last year. Research analysts forecast that Lantheus Holdings, Inc. will post 6.01 EPS for the current year.

Insiders Place Their Bets

In other news, Director Mary Anne Heino sold 26,066 shares of the firm's stock in a transaction dated Monday, June 2nd. The stock was sold at an average price of $76.83, for a total transaction of $2,002,650.78. Following the sale, the director now directly owns 318,650 shares in the company, valued at $24,481,879.50. This trade represents a 7.56% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Insiders own 1.50% of the company's stock.

Lantheus Company Profile

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.